These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31791649)

  • 21. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
    Cohen PR; Kato S; Goodman AM; Ikeda S; Kurzrock R
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy Advances in Urothelial Carcinoma.
    Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
    Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.
    Hamilton B; Xu K; Honeyball F; Balakrishnar B; Zielinski R
    Intern Med J; 2019 Aug; 49(8):1010-1015. PubMed ID: 30693623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New perspectives in Merkel cell carcinoma.
    Del Marmol V; Lebbé C
    Curr Opin Oncol; 2019 Mar; 31(2):72-83. PubMed ID: 30694842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
    Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
    Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
    Takahashi T; Tateishi A; Bychkov A; Fukuoka J
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
    Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
    J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R; Aubin F; Roche-Kubler B; Puzenat E
    Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
    Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
    J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
    Michalarea V; Fontana E; Garces AI; Williams A; Smyth EC; Picchia S; Rao S; Chau I; Cunningham D; Bali MA
    Curr Probl Cancer; 2019 Oct; 43(5):487-494. PubMed ID: 30827742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.